By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Caladrius Biosciences (Formerly Known As NeoStem, Inc.)  

420 Lexington Ave, Suite 350

New York  New York  10170  U.S.A.
Phone: 212-584-4180 Fax: 425-696-4651




Company News
Caladrius Biosciences (CLBS) Announces Enrollment Of The 70th Subject In The Phase II T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes 9/5/2017 9:19:57 AM
Caladrius Biosciences (CLBS) Reports 2017 Second Quarter Results 8/11/2017 8:20:38 AM
Caladrius Biosciences (CLBS) To Host 2017 Second Quarter Results Conference Call On August 10, 2017 At 4:30 P.M. Eastern Time 8/3/2017 1:08:57 PM
Caladrius Biosciences (CLBS) Announces That 50% Of Subjects Have Been Treated In The Phase II Clinical Trial Of CLBS03 For Type 1 Diabetes 7/19/2017 10:24:04 AM
Caladrius Biosciences (CLBS) Joins Russell Microcap Index 6/26/2017 9:45:41 AM
Caladrius Biosciences (CLBS) Closes The Sale Of Its Remaining Interest In PCT To Hitachi Chemical Co., Ltd. For $75 Million 5/19/2017 7:56:10 AM
Caladrius Biosciences (CLBS) Announces 2017 First Quarter Financial Results 5/16/2017 10:51:46 AM
Caladrius Biosciences (CLBS) To Hold 2017 Annual Stockholder Meeting On May 16 4/11/2017 10:59:01 AM
Caladrius Biosciences (CLBS) Announces Addition Of Four Clinical Sites, Including Joslin Diabetes Center, For The Ongoing Phase II Study Of CLBS03 In T1D 4/3/2017 1:47:03 PM
Hitachi Chemical Co., Ltd. Signs Agreement To Purchase From Caladrius Biosciences (CLBS) The Remaining 80.1% Interest In PCT For $75 Million 3/17/2017 11:08:03 AM